MX2022000136A - Ligandos del antigeno de membrana especifico de la prostata (psma) y usos de los mismos. - Google Patents

Ligandos del antigeno de membrana especifico de la prostata (psma) y usos de los mismos.

Info

Publication number
MX2022000136A
MX2022000136A MX2022000136A MX2022000136A MX2022000136A MX 2022000136 A MX2022000136 A MX 2022000136A MX 2022000136 A MX2022000136 A MX 2022000136A MX 2022000136 A MX2022000136 A MX 2022000136A MX 2022000136 A MX2022000136 A MX 2022000136A
Authority
MX
Mexico
Prior art keywords
psma
ligands
specific membrane
membrane antigen
prostate specific
Prior art date
Application number
MX2022000136A
Other languages
English (en)
Inventor
Lorenza Fugazza
Sangeeta Ray
Daniela Chicco
Maurizio F Mariani
Martin Gilbert Pomper
Original Assignee
Advanced Accelerator Applications Italy Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advanced Accelerator Applications Italy Srl filed Critical Advanced Accelerator Applications Italy Srl
Publication of MX2022000136A publication Critical patent/MX2022000136A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a ligandos del antígeno de membrana específico de la próstata (PSMA). En particular, la invención se refiere a ligandos de PSMA que tienen un resto glutamato-urea-lisina (GUL) y un agente quelante que puede comprender un radiometal.La invención además se refiere al uso de estos compuestos en la formación de imágenes y en el tratamiento del cáncer de próstata.
MX2022000136A 2019-07-02 2020-06-30 Ligandos del antigeno de membrana especifico de la prostata (psma) y usos de los mismos. MX2022000136A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19184015 2019-07-02
PCT/EP2020/068386 WO2021001360A1 (en) 2019-07-02 2020-06-30 Prostate specific membrane antigen (psma) ligands and uses thereof

Publications (1)

Publication Number Publication Date
MX2022000136A true MX2022000136A (es) 2022-04-27

Family

ID=67145647

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022000136A MX2022000136A (es) 2019-07-02 2020-06-30 Ligandos del antigeno de membrana especifico de la prostata (psma) y usos de los mismos.

Country Status (15)

Country Link
US (1) US20230226227A1 (es)
EP (1) EP3993837A1 (es)
JP (1) JP2022538478A (es)
KR (1) KR20220044496A (es)
CN (1) CN114341118A (es)
AR (1) AR119331A1 (es)
AU (2) AU2020299974A1 (es)
BR (1) BR112021026812A2 (es)
CA (1) CA3144557A1 (es)
CL (1) CL2021003525A1 (es)
CO (1) CO2021017708A2 (es)
IL (1) IL289039A (es)
MX (1) MX2022000136A (es)
TW (1) TW202114742A (es)
WO (1) WO2021001360A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023523235A (ja) * 2020-04-29 2023-06-02 ノバルティス アーゲー Ｐｓｍａ結合リガンドを放射標識するための方法及びそれらのキット

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040254102A1 (en) 2000-07-11 2004-12-16 Yuji Yoshiko Remedies for bone diseases
EP4374924A2 (en) * 2013-10-18 2024-05-29 Novartis AG Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
WO2017165473A1 (en) 2016-03-22 2017-09-28 The Johns Hopkins University Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer
WO2018222778A1 (en) * 2017-05-30 2018-12-06 The Johns Hopkins University Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer
AU2019217838C1 (en) * 2018-02-06 2024-05-02 Duke University PSMA targeted radiohalogenated urea-polyaminocarboxylates for cancer radiotherapy
US20210338846A1 (en) * 2018-07-30 2021-11-04 The Johns Hopkins University Competitive prostate-specific membrane antigen (psma) binding agents for reduction of non-target organ uptake of radiolabeled psma inhibitors for psma positive tumor imaging and radiopharmaceutical therapy

Also Published As

Publication number Publication date
IL289039A (en) 2022-02-01
CL2021003525A1 (es) 2022-10-21
AU2024200850A1 (en) 2024-02-29
AU2020299974A1 (en) 2022-01-27
KR20220044496A (ko) 2022-04-08
JP2022538478A (ja) 2022-09-02
BR112021026812A2 (pt) 2022-02-22
EP3993837A1 (en) 2022-05-11
TW202114742A (zh) 2021-04-16
US20230226227A1 (en) 2023-07-20
WO2021001360A1 (en) 2021-01-07
CA3144557A1 (en) 2021-01-07
CO2021017708A2 (es) 2022-05-20
AR119331A1 (es) 2021-12-09
CN114341118A (zh) 2022-04-12

Similar Documents

Publication Publication Date Title
PH12020551923A1 (en) Methods and compositions for treating cancer
ECSP21089217A (es) Quelantes macrocíclicos y métodos de uso de estos
SA517381703B1 (ar) C10orf54 - أجسام مضادة لـ واستخداماتها
SA518400222B1 (ar) أجسام مضادة لـ وتركيبات tim-3
AR110056A2 (es) Modulación de receptores quimiosensoriales y ligandos relacionados con los mismos
MY200609A (en) Antibodies binding to vista at acidic ph
PH12020550898A1 (en) Complex comprising a psma-targeting compound linked to a lead or thorium radionuclide
MX2020012091A (es) Composiciones anti-cd24 y usos de las mismas.
CL2017001580A1 (es) Anticuerpo o fragmento de anticuerpo contra cd38 anticuerpo humanizado, conjugado del anticuerpo con un compuesto citotoxico composición farmacéutica con dichos anticuerpos uso de los anticuerpos para tratar cáncer o enfermedad autoinmune método para diagnosticar cáncer polinucleotido vector y célula huésped.
GEP20217330B (en) Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
MY196631A (en) Antibody Agents Specific for Human Cd19 and uses Thereof
NZ760841A (en) Agonist antibodies that bind human cd137 and uses thereof
MX2021000392A (es) Anticuerpos anti-mesotelina.
MX2021003187A (es) Inhibición de la peptidasa específica de ubiquitina 9x.
MX2020002241A (es) Anticuerpos anti-tm4sf y métodos de uso de los mismos.
WO2019234241A8 (en) ANTI-oxMIF/ANTI-CD3 ANTIBODY FOR CANCER TREATMENT
MX2022004582A (es) Anticuerpo humanizado marcado con ri.
MX2021000213A (es) Anticuerpos de union al supresor de activacion de linfocitos t que contiene inmunoglobulina con dominio v (vista) a ph acidico.
PH12021551036A1 (en) Anti-liv1 immune cell cancer therapy
TN2019000211A1 (en) Antitumoral compounds
MX2022003212A (es) Anticuerpos anti-klk7, anticuerpos anti-klk5, anticuerpos multiespecificos anti-klk5/klk7 y metodos de uso.
EA201992318A1 (ru) Композиции и способы для диагностики и лечения рака предстательной железы с использованием молекулы, связывающей прогастрин
MX2020010104A (es) Conjugados de farmaco-anticuerpo anti-antigeno de membrana especifico de prostata (psma) humanizado.
MX2022003204A (es) Anticuerpos de union al supresor de activacion de linfocitos t que contiene inmunoglobulina con dominio v (vista) a ph acido.
MX2022000136A (es) Ligandos del antigeno de membrana especifico de la prostata (psma) y usos de los mismos.